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Tuning the binding affinity and selectivity of perfluoroaryl-stapled 
peptides by cysteine-editing 
Sanne J.M. Verhoork,[a] Claire E. Jennings,[b] Neshat Rozatian,[c] Judith Reeks,[b] Jieman Meng,[b] Emily 
K. Corlett,[c] Fazila Bunglawala,[a] Martin E.M. Noble,[b] Andrew G. Leach,[a] and Christopher R. Coxon*[a]  
 
Abstract: A growing number of approaches to ‘staple’ α-helical 
peptides into a bioactive conformation using cysteine cross-linking are 
emerging. Here we explore the replacement of L-cysteine with 
‘cysteine analogues’ in combinations of different stereochemistry, 
side chain length and beta-carbon substitution, to examine the 
influence that the thiol-containing residue(s) has on target protein-
binding affinity in a well explored model system, p53-MDM2/MDMX. 
In some cases, replacement of one or more L-cysteine residues 
afforded significant changes in the measured binding affinity and 
target selectivity of the peptide. Computationally constructed 
homology models indicate that some modifications, such as 
incorporating two D-cysteines favourably alter the positions of key 
functional amino acid side chains, which is likely to cause changes in 
binding affinity, in agreement with measured SPR data. 
Linear, unstructured peptide sequences often suffer from low 
proteolytic stability when excised from their parent proteins, 
limiting their development as potential therapeutics. Stapled α-
helical peptides (SAHs) are a highly-promising class of 
therapeutic agent, which are designed to mimic an α-helical motif 
of a protein, and have superior proteolytic stability in vivo over the 
equivalent unconstrained peptide.[1] The most common method of 
peptide stapling employs the use of the all-hydrocarbon (alkene) 
linker developed by Grubbs and Blackwell,[2-4] and pioneered by 
the Verdine Group. This strategy is used to stabilise a peptide α-
helix and can often deliver impressive biological activity through 
steric constraint of a bio-active conformation.[5] Using the alkene 
metathesis approach requires the incorporation of α,α-
disubstituted alkene-containing amino acids into the peptide 
sequence. Typically, these building blocks are either purchased 
at significant expense or can be obtained by multistep synthesis 
using, for example, nucleophilic glycine equivalents.[6] The 
standard all-hydrocarbon stapling approach typically incorporates 
a combination of R,S- or S,R- α,αʹ-disubstituted alkenyl amino 
acids with optimised chain length.[7,8] It is well known that linker 
length, linker orientation and linker type of the stapled peptides 
can affect the binding properties.[9, 10] Typically, the rationale for 
inclusion of an additional α-methyl group was to overcome the 
perceived destabilising effect upon helical conformation by 
introducing D-amino acids.[7] However, mono-substituted α-
alkenyl amino acids have been shown to be similarly effective.[11] 
The importance of stereochemical effects on the helical character 
and, thus, biological activity have been clearly demonstrated in 
the alkene metathesis i,i+4 peptide stapling approach.[12]  
The recent literature has shown a significant surge in 
interest in the two-component chemoselective cross-linking of 
peptides via e.g., ‘double-click’ CuAAC chemistry.[13-15] Most often, 
however, cysteine thiol residues have provided an excellent 
handle for peptide stapling, driven mainly by the ease and 
relatively-low cost of obtaining the linear pre-stapled peptide. This 
topic has been recently reviewed by Fairlie.[16] Example thiol 
cross-linkers include, the use of dibromomaleimide,[17] 
dichloroacetone,[18] 1-,4-dichlorotetrazine,[19] 1,2,4,5-
tetrabromodurene,[20] α , α ′ -dibromo-m-xylene,[21] trans-1,4-
dibromo-2-butene and cis-1,4-dichloro-2-butene[22] and 
perfluoroaryl reagents.[23] Whilst significant attention has focussed 
on the nature of the crosslinking electrophile, comparatively little, 
if any attention has focused on the cysteines, with the single 
exception of introducing homocysteine.[17] The distance between 
the cysteine residues has been explored and optimised, albeit in 
non-helical systems,[24] yet the stereochemistry of cysteine has 
not been taken into account, in terms of the consequences on 
biological activity and the position of key amino acid side chain 
residues. By drawing analogy with the traditional all-hydrocarbon 
approach, we investigated the replacement of L-cysteine 
(cysteine-editing) with selected combinations of D-cysteine, 
homocysteine and penicillamine to examine the effect of i) 
stereochemistry, ii) cysteine homologation, and iii) beta-carbon 
substitution. We considered that the outcomes will be directly 
important to the cysteine-stapling work of other groups as 
highlighted above. 
 
Scheme 1. Synthesis of perfluoroaryl-stapled peptides. 
The p53-MDM2 and p53-MDMX protein-protein interactions were 
selected as a model system in which to study cysteine-editing, 
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due to its well characterised interaction and the availability of 
published known stapled α-helical peptide inhibitors.[13, 14, 25-27] 
The p53 tumour suppressor is a major regulator of the cell cycle 
and is activated in response to genotoxic stress resulting from 
oncogenic signalling and exposure to, for example, ionising 
radiation and carcinogenic agents.[28] Through its role as a 
transcription factor, p53 induces cell cycle arrest and apoptosis in 
afflicted cells,[29] fulfilling a critical role in the maintenance of 
healthy functioning of cells and the avoidance of malignancy. A 
12 amino acid peptide LTFEHYWAQLTS (PDI peptide) identified 
by phage display[30] was reported to disrupt the p53-MDM2 
protein-protein interaction and has previously been stapled using 
non-hydrocarbon techniques.[31,32] This served as a test-bed for 
diversification in our studies. The key features of this peptide (and 
indeed, the p53 protein) that promote the biological activity are 
the three amino acids, Phe, Trp and Leu, with the positions being 
important for activity. These residues were retained and other 
selected residues that were previously reported to be tolerant to 
substitution[31] were replaced with cysteine analogues in the PDI 
sequence with the standard relative spacing of four (i, i+4) amino 
acids, corresponding to equivalent positions at neighbouring turns 
on the α-helix. Six different combinations were synthesised using 
solid phase peptide synthesis on Rink amide resin to afford the C-
terminal amide of the form Ac-LTF(AAi)HYW(AAi+4)QLTS (Table 
1). Stapling was performed using the cross-linking reagent 
hexafluorobenzene (Scheme 1) as demonstrated by Pentelute 
and co-workers[23] due to an ongoing interest in related reactions 
in our laboratory. In each case the thiol-crosslinking occurred 
cleanly under relatively mild conditions (25 mM DIPEA in DMF, 
room temperature, <4.5 h).[33, 34] 
The binding affinity of the synthesised p53-mimicking 
peptides 1 and 7-12 were examined by measuring dissociation 
constants (Kd) for their interactions with GST-MDM2 (17-125) and 
GST-MDMX (22-111) constructs using surface plasmon 
resonance (SPR) (Table 1 and supporting information). Binding 
affinities were measured for the PDI peptide and the cis-
imidazoline small molecule, nutlin-3a as positive binding controls 
and to validate the SPR approach against a biochemical HTRF 
assay (see supporting information). SPR evaluation identified a 
number of highly potent tetrafluorobenzene-cross-linked SAHs 
with low-to-moderate micromolar affinities for MDM2 and MDMX 
as measured by Kd values. In general, the perfluoroaryl-stapled 
peptides had higher Kd (lower affinity) than the phage display PDI 
peptide; however, the additional proteolytic stability gained from 
this modification[23] (see supporting information) may offset the 
sacrifice in affinity. In fact, introduction of L-cysteine residues into 
the non-stapled PDI analogue (1) decreased equally binding 
affinity for both MDM2 and MDMX compared with PDI. In any 
case, the primary purpose of this study was for comparison of the 
parent 7 (L-Cys, L-Cys) with peptides with different cysteine 
analogues comprising the cross-link. One particularly interesting 
outcome is that most of the stapled peptides (7 (> 2-fold), 9 (> 4-
fold), 10 (> 3.5-fold)) had a generally higher affinity for MDMX 
compared with MDM2, whereas, PDI and 1 were equipotent for 
each isoform, albeit with lower Kd values. In general, changing a 
single cysteine stereochemistry from L- to D- at i or i+4 positions 
was well tolerated by both MDM2 and MDMX, however, MDMX 
appeared generally more tolerant to ‘cysteine-editing’ than MDM2. 
Inversion of both L- i and i+4 α-carbon substituents to the D-
configuration (10) significantly enhanced the affinity for both 
MDMX (~7-fold) and MDM2 (~5 fold) compared with 7. This has 
particular importance as peptides comprising D-amino acids are 
typically more resistant to proteolytic degradation than their 
canonical counterparts.  
Most notably, branching of L-cysteine at the β-position with 
geminal-dimethyl groups (L-penicillamine, 12) exhibited a 
significantly higher Kd than all other analogues, indicating lower 
affinity for both MDM2 (>16-fold vs iL-Cys, i+4L-Cys, 7) and MDMX 
(~22-fold vs iL-Cys, i+4L-Cys, 7). This may suggest that the L-Pen-
containing peptide is significantly distorted from a well-defined α-
helix or presents destabilising interactions. In stark contrast, 
homologation of the i, i+4 cross-linker through incorporation of 
homocysteine (11) appeared to be much better tolerated than L-
cysteine, affording around a 7-fold lower Kd (7-fold higher affinity) 
for MDM2 and 3-fold lower for MDMX versus the parent 7. This 
was around equipotent with the non-stapled 1, which itself was 
also non-selective for either MDM2 or MDMX. Overall, the 
observed SARs may be related to the geometric constraints 
imposed by the cysteine analogue and the cross-linker, and the 
resulting impact upon the helicity of the peptide and the relative 
positions of key amino acid side chains, Phe, Trp and Leu. 
Table 1. Dissociation constants (Kd) for peptides (1, 7-12) binding to 
MDM2/MDMX attained from an SPR assay and comparison with control inhibitor 
nutlin 3a and PDI peptide. Note: hCys = homocysteine, Pen = penicillamine. 
Peptide AAi AAi+4 Cross-linker Kd /µM Chi² (RU²) 
    MDM2 MDMX MDM2 MDMX 
PDI  L-Glu L-Ala - 0.04 0.02 1.36 0.82 
Nutlin 3a  - - - 0.17 ND 0.24 ND  
1 L-Cys L-Cys - 0.18 0.18 1.49 0.40 
7 L-Cys L-Cys  
 
1.02 0.44 2.37 0.81 
8 L-Cys D-Cys 0.41 0.37 3.08 0.99 
9 D-Cys L-Cys 1.70 0.40 3.69 6.49 
10 D-Cys D-Cys 0.22 0.06 1.71 0.86 
11 L-hCys L-hCys 0.14 0.15 4.07 2.91 
12 L-Pen L-Pen 16.90 9.89 10 8.17 
 
Chart 1. Comparison of binding affinities (Kd) for stapled peptides containing 
alternative cysteine analogues. 
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In light of these observations, we employed an in silico modelling 
approach (Figure 1) to understand the structural and 
conformational consequences of cysteine-replacement. The 
apparent α-helicity of 7 was initially measured using circular 
dichroism but produced poor results (see supporting information) 
due to the absorbance of the fluoroaryl moiety at 222 nm, which 
was consistent with previous literature reports.[17] Molecular 
dynamics simulations were performed starting from homology 
models for the free peptides 1 - 6.  The homology model used the 
sequence and chain B from the structure of human MDM2 in 
complex with the reported high affinity PDI peptide (PDB code: 
3G03), where the Phe, Trp and Leu residues provide key points 
of interaction with MDM2 (Figure 1A). In order to benchmark 
simulations of the cysteine replacement peptides, this native 
ligand was also simulated in the same way as described below for 
the cross-linked complexes. In each simulation, the resulting 
geometries were assessed for their ability to place the three key 
binding residues in appropriate positions for MDM2 interaction. 
This used an analogy to pharmacophore triplets, a commonly 
used description in chemoinformatics that uses the three-
dimensional positioning of three pharmacophoric points (usually 
key interactions such as hydrogen bonding groups or hydrophobic 
groups) as a descriptor and benefits from the ease of analysis and 
understanding of the geometry of triangles. In this case, two 
triangles have been used to describe how modification of the 
peptide alters the positions of Phe, Trp and Leu sidechains: one 
triangle formed from the three C atoms and the second from the 
three C atoms, shown as dashed lines in Figure 1A. This initial 
analysis reveals that the two triangles are rather similar because 
the C-C bonds are all pointed in approximately the same 
direction and this is clearly an important part of how the peptide 
forms tight interactions with the receptor. 
 
A 
 
 Xtal. Sim.  7    8    9   10    11   12 
C
Compound 11                                       Compound 12 
Figure 1. A) X-ray structure of MDM2-PDI peptide complex (PDB: 3G03) with 
Cα and Cβ triangles shown with dotted yellow lines. B) Comparison of simulated 
cross-linked peptide Phe, Trp and Leu side chain positions. Note: Xtal = from X-
ray structure 3G03, Sim = simulated PDI peptide. C) Simulated models of 11 
and 12, providing possible interactions with MDM2. 
The simulations of the cross-linked peptides involved two stages: 
1) the peptide with the two cysteines in their free thiol form was 
simulated (in MOE using default settings) starting from each of 
the nine possible rotamers of the cysteine (arising from rotation 
about the C-C bond in each of the cysteines); 2) the rotamer that 
positioned the two sulfur atoms closest to the separation between 
the two atoms in the cyclised adduct (6.37 Å) was selected and 
the linker was introduced by editing the molecule in MOE. The 
edited structure was energy minimised and a second simulation 
performed. In both stages, the default settings in MOE were 
employed.  This entails use of the NPA algorithm, using the 
AMBER10 forcefield with implicit solvation (with interior dielectric 
of 1 and exterior dielectric of 80).  An initial 100 ps of equilibration 
was followed by 500 ps of production of which the second half 
(last 250 ps) is used in the analysis (reported every 0.5 ps giving 
a total of 500 data points from each simulation). The simulations 
can be summarised succinctly by considering the average values 
of each side of the triangle equivalent to those shown in Figure 
1B.  
When the average distances are compared with those 
observed in the published MDM2 complex, an RMSD can be 
computed to permit an overall comparison of how well the free 
stapled peptide retains the geometry required for complex 
formation. This suggests that the double D-Cys-containing 
stapled peptide 10 (RMSD = 1.0 Å) will retain the required 
pharmacophoric arrangement better than even the native peptide, 
which adopts a slightly different geometry when free from the 
receptor. The next best is predicted to be compound 8 (RMSD = 
1.2 Å), followed by 12 and 7. The simulations correctly identify 10 
as the best of the analogues in which only stereochemistry is 
varied, whereas, compound 9 can be considered the least 
suitable by this measure. Whilst this is in good agreement with the 
SPR data for stereoisomeric peptides, the approach does not 
appear able to correctly rank the structural variations in which 
methylation or homologation have been introduced, indicating 
that other factors also govern their interaction and affinity with the 
protein. In order to provide insight into these two structures, 
molecular editing in MOE was used to convert the native complex 
to the stapled form for compounds 11 and 12. The complex was 
then simulated to investigate any extra contacts made by these 
two linkers that could explain the observed binding. The final 
snapshot is shown in Figure 1C and reveals that 11 is able to lay 
its linker on a hydrophobic part of the receptor surface. While 
compound 12 is also able to form some hydrophobic interactions, 
the shape of this linker is not amenable to making continuous 
contact because of the protrusion of one of the methyl groups in 
the penicillamine.  These are particularly close to the sidechain of 
Met62 which is in a more constrained environment when 
compound 12 is bound. Overall, these insights help to explain the 
differential measured binding affinities following cysteine editing.  
This work has demonstrated that the conformational 
properties of a stapled peptide, and thus the biological activity, 
can be modified by the nature (size and stereochemistry) of the 
thiol groups to be cross-linked; and indeed, the combination of 
these with a suitable cross-linker. This has clear implications in 
the tuning of binding affinity and/or target selectivity in two-
component disulfide-stapling of α-helical peptides and provides 
an important new tool in this rapidly growing area. 
	 	 	 	 	 12	al.	 i .	
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Experimental Section 
Materials. All Fmoc L- and D-amino acids (CEM), Rink Amide ProTide 
resin (CEM), diisopropylcarbodiimide (DIC; Apollo Scientific), Oxyma 
PureTM (CEM), N.N'-dimethylformamide (DMF; Fisher Scientific), 
diisopropylethylamine (DIPEA; Merck Millipore) and piperidine (Merck 
Millipore) were purchased from commercial suppliers and used directly as 
indicated in the appropriate experimental procedures. All other reagents 
(hexafluorobenzene, trifluoroacetic acid (TFA), triisopropylsilane (TIPS) 
were purchased from Sigma Aldrich and solvents (HPLC grade) were 
purchased from Fisher Scientific. Nutlin-3a was purchased from 
NewChem Technologies Ltd, Newcastle upon Tyne, UK. 
Solid phase peptide synthesis (SPPS) of peptides 1 – 6 and PDI 
peptide. Each linear thiol-containing peptide sequence was prepared 
using automated Fmoc-SPPS methods on a Liberty Blue microwave-
assisted peptide synthesiser (CEM). Solid phase synthesis was conducted 
using Rink amide ProTide resin (180 mg, 0.56 mmol/g loading; 0.1 mmol), 
employing the required Fmoc amino acids (0.2 M in DMF; 5 eq.); with DIC 
(1M stock solution in DMF; 10 eq.), Oxyma Pure (1M stock solution, 5 eq) 
and piperidine (20% v/v in DMF; 587 eq., 4 mL) as activator, and 
deprotection, respectively. Standard coupling procedures employed 
double coupling of each amino acid (2.5 min, 90 °C). Amino acids bearing 
thermally-sensitive protecting groups e.g., Fmoc-L-Cys(Trt)-OH, Fmoc-D-
Cys(Trt)-OH, Fmoc-Pen(Trt)-OH, Fmoc-hCys(Trt)-OH and Fmoc-
His(Boc)-OH were coupled under milder conditions (50°C for 10 min). 
Following on-resin synthesis of the appropriate sequence, N-terminal 
capping was performed using Ac2O/DMF (20% v/v, 2 x 15 min) with 
shaking at room temperature. Finally, peptides were cleaved from the resin 
as the C-terminal amide by treatment with a cleavage cocktail (5 mL; 
comprising TFA, TIPS and water (9 : 0.5 : 0.5 v/v) with regular shaking at 
room temperature for 4 h. Peptides were precipitated from cleavage 
solutions by dropwise addition into cold diethyl ether followed by 
centrifugation. The resulting pellet was successively suspended in cold 
diethyl ether and centrifuged twice further. The solids obtained were 
dissolved in water/MeCN (depending upon solubility), frozen and 
lyophilised. PDI and peptide 1 were purified by semi-preparative HPLC 
(see supporting information). The crude disulfide peptides 1 - 6 were used 
without further chromatographic purification.  
Synthesis of perfluoroaryl-stapled peptides 7 - 12. To a centrifuge tube 
containing solid crude peptide 1 - 6 (approx. 50 mg) was added DIPEA 
stock solution (25 mM in DMF, 1.0 mL), followed by hexafluorobenzene 
(20 eq., 0.66 mmol). The resulting mixture was shaken at room 
temperature for 4.5 h. After precipitation in Et2O (as above), the resulting 
crude stapled peptide was redissolved in a mixture of water/MeCN (exact 
amounts depended on solubility). Crude samples were purified using semi-
preparative HPLC. Stapled peptides were characterised by analytical 
HPLC and high resolution mass spectrometry (see supporting information).  
Protein Expression and Purification. PCR amplified DNA encoding 
MDM2 17-125 and MDMX 22-111 was cloned into pGEX 6P-1 to allow 
expression as GST fusion proteins. Recombinant DNA was transformed 
into E.coli BL21(DE3) pLysS for expression in LB media at 18°C and 160 
rpm following IPTG induction (100 mM) at an OD600 of 0.6-1.0. Following 
overnight incubation, cultures were harvested, sonicated and the fusion 
proteins were purified from the resulting cell lysate using GST-affinity 
chromatography and gel filtration, using a HiLoad® 26/60 Superdex® 75 
column equilibrated in mHBS (20 mM HEPES, 100 mM NaCl, 5 mM DTT, 
pH 7.4). Fractions containing purified protein were pooled, concentrated 
and frozen at - 80°C before performing SPR analysis.  
 
Surface Plasmon Resonance (SPR) binding experiments. SPR 
experiments were performed on a Biacore S200 instrument (GE 
Healthcare) at 25°C using a Series S carboxyl-derivatized sensor chip 
(CM5) prepared for capture of GST, GST-MDM2 and GST-MDMX 
following immobilisation of anti-GST antibody using GST-capture and 
amine coupling kits (GE Healthcare). A running buffer containing 10 mM 
HEPES, pH 7.4, 150 mM NaCl, 0.05% Tween 20 and 3 mM EDTA was 
used during sensor chip preparation. Polyclonal goat Anti-GST antibody 
(30 µg/mL) was prepared in immobilisation buffer (10 mM sodium acetate, 
pH 5.0) and was immobilised to the CM5 chip through amine coupling after 
injection of EDC/NHS (1:1) onto the sensor chip surface for a contact time 
of 840 s and at a flow rate of 5 µL/min. The antibody was injected onto the 
activated surface for 600 s at 5 µL/min and unreacted groups were then 
deactivated by injection of ethanolamine for 420 s at 10 µL/min. High 
affinity sites were blocked by injecting recombinant GST (5 µg/mL in 
running buffer) twice for 300 s at 5 µL/min prior to regenerating the sensor 
surface through injection of regeneration solution (10 mM glycine-HCl, pH 
2.1) for 120 s at 10 µL/min.  
Analytes were dissolved in 100% DMSO to 20 mM and an Echo 550 
acoustic dispenser (Labcyte) was used to dispense 12 concentration-
response points for each analyte, as 1 µL droplets into a 384 well 
microplate (Greiner). The droplets were diluted (1:100) with 99 µL of 
running buffer supplemented with 1 mM DTT prior to analysis. As for the 
analytes, 100% DMSO was also acoustically dispensed and diluted as a 
12-point concentration series to allow for solvent correction during analysis. 
Freshly thawed GST or GST-fusion protein diluted in running buffer was 
applied to reference or test channels respectively for 600 s or until 
satisfactory response unit levels (>1000 RU) had been achieved. Binding 
experiments were performed at a flow rate of 30 µL/min using multi-cycle 
kinetics with injection of analytes over the captured ligand for a contact 
time of 60 s, followed by a dissociation period of 1500 s, with multi-channel 
data collection at 10 Hz.  During multicycle analysis, running buffer was 
modified with 1 mM DTT and 1% (v/v) DMSO to match with analyte 
composition.  Data evaluation was performed using Biacore S200 
Evaluation software (Version 1.0, Build 20) with binding curves fit to a 1:1 
(Langmuir) interaction model for evaluation of kinetic and affinity 
parameters, following solvent correction and reference channel 
subtraction.   
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